- Study type: Randomised Clinical Trial, Treatment
- Study type descriptors: Randomised controlled trial, Single centre
- Objective: To test the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of the monoclonal antibody Drug B10-FC in healthy volunteers with three dose-escalation groups and patients with a confirmed diagnosis of COVID-19
- Number of participants enrolled: Enrollment data not available
- Study enrolling from to
- Study includes follow-up for 1 month
Study Data
- Adults (18-64 years)
- General population
- Outpatient clinic
- SARS-CoV-2
- Pharmacological intervention
- Monoclonal antibodies
External Links
Other information
If you would like to contact the Principal Investigator of the study please email: ccb@ateneo.univr.it
The data is updated up to